During the past decade, Hospital Cardiologica Aguascalientes conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 20 clinical trials were completed, i.e. on average, 87% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 15 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Cardiologica Aguascalientes" #1 sponsor was "Boehringer Ingelheim" with 10 trials, followed by "Allergan" with 4 trials sponsored, "Pfizer" with 3 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Cardiologica Aguascalientes" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "ICON plc" with 1 trials as a collaborator, "Medidata Solutions" with 1 trials as a collaborator, "PPD" with 1 trials as a collaborator and "Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Cardiologica Aguascalientes" are "Gastroparesis" (4 trials), "COVID-19" (3 trials), "Cardiovascular Disease" (3 trials), "Diabetes Mellitus" (3 trials) and "Heart Failure" (3 trials). Many other conditions were trialed in "Hospital Cardiologica Aguascalientes" in a lesser frequency.

Most popular intervention types in "Hospital Cardiologica Aguascalientes" are "Drug" (26 trials), "Other" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Empagliflozin" (3 trials), "Relamorelin" (3 trials), "bococizumab (PF-04950615)" (2 trials) and "Alteplase" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Cardiologica Aguascalientes" are 27 trials for "All" genders.

Currently, there are NaN active trials in "Hospital Cardiologica Aguascalientes". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Hospital Cardiologica Aguascalientes, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Cardiologica Aguascalientes, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".